Adlai Nortye
Adlai Nortye
ANL
NASDAQ
2.83
USD
29.82%
About
Adlai Nortye Ltd is a global clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The Company’s pipeline includes three clinical-stage drug candidates, buparlisib (AN2025), palupiprant (AN0025), and AN4005, as well as three preclinical candidates.
AN2025 is a pan-phosphoinositide 3-kinase (PI3K) inhibitor that is designed to act against solid tumors. AN2025 is undergoing Phase III, open-label clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas (HNSCC) after anti-programmed death-1 (PD-1) or its ligand (PD-L1) treatment.
AN0025 is a small molecule prostaglandin E receptor 4 (EP4) antagonist. AN4005 is an internally discovered oral small molecule PD-L1 inhibitor in development to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include: AN8025, AN1025, and AN9025..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 9.7K |
| Three Month Average Volume | 231.8K |
| High Low | |
| Fifty-Two Week High | 19.2999 USD |
| Fifty-Two Week Low | 2.69 USD |
| Fifty-Two Week High Date | 29 Sep 2023 |
| Fifty-Two Week Low Date | 26 Aug 2024 |
| Price and Volume | |
| Current Price | 2.8334 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | -18.97% |
| Thirteen Week Relative Price Change | -63.54% |
| Twenty-Six Week Relative Price Change | -67.38% |
| Fifty-Two Week Relative Price Change | -99,999.99% |
| Year-to-Date Relative Price Change | -73.39% |
| Price Change | |
| One Day Price Change | 3.03% |
| Thirteen Week Price Change | -60.97% |
| Twenty-Six Week Price Change | -64.13% |
| Five Day Price Change | -5.24% |
| Fifty-Two Week Price Change | -99,999.99% |
| Year-to-Date Price Change | -68.48% |
| Month-to-Date Price Change | -19.05% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 2.15183 USD |
| Book Value Per Share (Most Recent Quarter) | 1.44628 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 2.15012 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.44489 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -3.123 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.34608 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.24645 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -7.25883 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -6.2148 USD |
| Normalized (Last Fiscal Year) | -7.25883 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -7.25883 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -6.2148 USD |
| Including Extraordinary Items (Last Fiscal Year) | -7.25883 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -6.2148 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.66933 USD |
| Cash Per Share (Most Recent Quarter) | 2.65545 USD |
| Cash Flow Per Share (Last Fiscal Year) | -7.17315 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -2.60033 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -3.29936 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -1,339 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -1,068.44% |
| Pretax Margin (Last Fiscal Year) | -2,084.56% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -1,351.02% |
| Operating Margin (Trailing Twelve Months) | -1,293.38% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -2,097.42% |
| Net Profit Margin (Trailing Twelve Months) | -1,081.30% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -99,999.99% |
| EPS Change (Trailing Twelve Months) | -99,999.99% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -58,459,000 |
| Net Debt (Last Fiscal Year) | -66,951,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 21 |
| Price to Sales (Trailing Twelve Months) | 21 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 1 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 2 |
| Current Ratio (Most Recent Quarter) | 2 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -56,852,000 |
| Free Cash Flow (Trailing Twelve Months) | -66,937,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -2 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 40 |
| Total Debt to Equity (Most Recent Quarter) | 74 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -103.43% |
| Return on Assets (Trailing Twelve Months) | -99,999.99% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -99,999.99% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -99,999.99% |
| Return on Investment (Trailing Twelve Months) | -99,999.99% |
| Return on Investment (5 Year) | -99,999.99% |